Hamilton Robotics and Promega to Collaborate
News Aug 27, 2009
Hamilton Robotics and Promega Corporation announced today that the two companies will collaborate in the development of an automated system for the isolation of genomic DNA from large-volume blood samples.
Based on Hamilton’s MICROLAB® STAR liquid handling technology and Promega systems and reagents, the new offering will increase throughput for large-volume applications such as biobanking, pharmacogenomics and genetic research.
“Hamilton’s air displacement pipetting technology offers a number of unique advantages over other robotics systems,” explained Jeff Briganti, strategic marketing manager for Promega. “We have already successfully collaborated with them to create and optimize automated protocols for several applications. This collaboration takes the relationship one step further toward the codevelopment of an entire system.”
Although life science research has seen a recent overall trend toward miniaturization, several genetic analysis applications require the ability to isolate DNA from large sample volumes. Automated large-volume liquid handling poses specific challenges that Hamilton has been able to address, most recently with the introduction of its 5ml independent pipetting channels and 5ml disposable tips for the MICROLAB STAR platform.
Promega’s new method employs next-generation technology and novel chemistry, allowing for an automated process with increased recovery, higher concentration and enhanced purity of gDNA isolated from large-volume blood samples compared to previous automated techniques.
Hamilton and Promega expect to launch the new system later this year.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.